The rise of Viagra and its influence on the medicinal landscape presents a intricate question for shareholders. While the initial sales statistics were astounding, the exclusivity has lapsed, leading to a flood of copycat alternatives that are chipping away at revenue. Furthermore, the sector is facing issues related to aging trends and evolving… Read More